...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiovascular pharmacology and therapeutics >Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia
【24h】

Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia

机译：空腹血糖，高血压和混合血脂异常的患者中，马尼地平加瑞舒伐他汀与奥美沙坦加瑞舒伐他汀对胰岛素抵抗指标的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To compare the effect of manidipine 20 mg plus rosuvastatin 10 mg versus olmesartan 20 mg plus rosuvastatin 10 mg on markers of insulin resistance in patients with mixed dyslipidemia, hypertension, and impaired fasting glucose (IFG). Methods: This study had a prospective, randomized, open-label, blinded endpoint (PROBE) design. A total of 40 patients with IFG, mixed dyslipidemia, and stage 1 hypertension were included. Following dietary intervention, patients were randomly allocated to rosuvastatin (10 mg/d) plus olmesartan (20 mg/d) or manidipine (20 mg/d). The primary end point was the between-group difference in changes in the Homeostasis Model Assessment Insulin Resistance (HOMA-IR) index following 3 months of treatment. Secondary end points included changes in fasting plasma glucose (FPG), fasting insulin levels, and glucosylated hemoglobin. Results: At the end of the 3-month treatment period, a significant increase in HOMA-IR index by 14% (from 2.4 [0.5-7.9] to 2.7 [0.5-5.2], P = .02 versus baseline) was seen in the olmesartan plus rosuvastatin group. On the contrary, no significant change in HOMA-IR index was observed in the manidipine plus rosuvastatin group (1.7 [0.5-5.2] to 1.7 [0.8-6.0], P = NS versus baseline, P = .04 versus olmesartan plus rosuvastatin group). An increase in fasting insulin levels was observed in the olmesartan plus rosuvastatin group (+8%, from 10.1 [2.0-29.6] to 10.9 [2.0-19.1] μU/mL, P > .05 versus baseline), while no significant change was seen in the manidipine plus rosuvastatin group (+3%, from 7.3 [2.0-17.6] to 7.5 [1.9-15.6] μU/mL, P = NS versus baseline, P = .02 versus olmesartan plus rosuvastatin group). Fasting plasma glucose and glycosylated hemoglobin did not change significantly in any group. Conclusion: Manidipine seems to ameliorate the possible statin-associated increase in insulin resistance as compared with olmesartan in patients with IFG, hypertension, and mixed dyslipidemia.
机译：目的：为了比较混合性血脂异常，高血压和空腹血糖（IFG）患者中，马尼地平20 mg加罗舒伐他汀10 mg与奥美沙坦20 mg加罗舒伐他汀10 mg对胰岛素抵抗标志物的作用。方法：本研究采用前瞻性，随机，开放标签，盲目的终点（PROBE）设计。总共包括40例IFG，混合血脂异常和1期高血压的患者。通过饮食干预后，患者被随机分配罗苏伐他汀（10 mg / d）加奥美沙坦（20 mg / d）或马尼地平（20 mg / d）。主要终点是治疗3个月后体内稳态模型评估胰岛素抵抗（HOMA-IR）指数变化的组间差异。次要终点包括空腹血糖（FPG），空腹胰岛素水平和糖基化血红蛋白的变化。结果：在3个月的治疗期结束时，HOMA-IR指数显着增加了14％（从2.4 [0.5-7.9]增至2.7 [0.5-5.2]，相对于基线，P = .02）奥美沙坦加瑞舒伐他汀组。相反，在马尼地平加罗苏伐他汀组中，HOMA-IR指数未见明显变化（1.7 [0.5-5.2]至1.7 [0.8-6.0]，P = NS与基线相比，P = .04与奥美沙坦加罗舒伐他汀组）。在奥美沙坦加罗苏伐他汀组中观察到空腹胰岛素水平增加（+ 8％，从10.1 [2.0-29.6]μU/ mL，相对于基线，P> .05），但无明显变化在马尼地平加瑞舒伐他汀组中观察到（+ 3％，从7.3 [2.0-17.6]至7.5 [1.9-15.6]μU/ mL，P = NS与基线相比，P = .02与奥美沙坦加罗舒伐他汀组）。空腹血糖和糖基化血红蛋白在任何组中均无明显变化。结论：与奥美沙坦相比，IFG，高血压和混合血脂异常患者中，马尼地平似乎可以改善他汀类药物相关的胰岛素抵抗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号